Patent · US Active

Endostatin mutants with mutations at ATP binding sites

US10647968B2 · kind B2 · utility

0Cited by

1References

6Claims

0Family size

Assignees

TSINGHUA UNIVERSITY · CN
BEIJING PROTGEN LTD. · CN

Inventors

Yongzhang Luo · Beijing, CN
Peng Liu · Beijing, CN
Xinan LU · Beijing, CN
Yang Chen · Ambler, US
Yan Fu · Shanghai, CN
Guodong Chang · Beijing, CN
Daifu Zhou · Beijing, CN

Key dates

Filing date	Sep 10, 2012
Grant date	May 12, 2020
Priority date	—
Expiry date	May 20, 2033

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention discloses a new anti-tumor medicament comprising a mutant of endostatin. The mutant comprises a mutation in the ATP-binding site of endostatin and has a decreased ATPase activity and an increased anti-angiogenesis activity.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.